Latest Administration News

Artrya Limited has secured FDA 510(k) clearance for its Salix Coronary Plaque module, enabling near real-time detection of high-risk coronary artery plaque and opening a lucrative U.S. market opportunity with a $950 reimbursement per scan.

IPH Limited reported a solid 16.5% revenue increase to $710.3 million for FY25, driven by strategic acquisitions in Canada and strong organic growth in Asia and ANZ. Despite ongoing delays at the Canadian Intellectual Property Office, the company achieved higher earnings and dividends, setting the stage for further operational efficiencies and technology investments.

IPH Limited reported a robust FY25 with revenue rising 16.6% to $710.3 million and net profit after tax up 13.2% to $68.8 million, driven by strategic acquisitions and a pivot towards organic growth and AI integration.

Insignia Financial has reported a robust FY25 with a 17.6% rise in underlying net profit after tax and a record $330.3 billion in funds under management. The company also unveiled its ambitious strategy to become Australia's leading diversified wealth manager by 2030.

Insignia Financial delivered a robust FY25 performance with an 18% rise in underlying net profit after tax, driven by higher funds under management and cost efficiencies, while announcing a $3.3 billion acquisition agreement with CC Capital Partners.

Insignia Financial reported a robust 17.6% rise in underlying net profit after tax for FY25, driven by strategic cost optimisation and business simplification. The company also unveiled plans to relaunch its MLC brand and outlined confident guidance for FY26.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Astron Corporation Limited is set to redomicile from Hong Kong to Australia through a scheme of arrangement, creating a new Australian parent company, Aus NewCo. This move aims to align the corporate structure with its Australian assets and simplify shareholder voting.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Universal Biosensors Pty Limited has entered voluntary administration with KPMG appointed as administrators, signaling urgent financial distress and a potential restructuring ahead.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.